## Amendment Tool

v1.6 06 December 2021

QC: No

Short project title*:	Perioperative Quality	Improvement Prog	amme (PQIP)			
IRAS project ID* (or REC reference if no IRAS project ID is available):	215928					
Sponsor amendment reference number*:	Substantial Amendm	ent SA7				
Sponsor amendment date* (enter as DD/MM/YY):	18 August 2023					
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	The study end date is PQIP is now support We are therefore upp recruitment target of trials whichever is lat be recruited for a sec consent form within t consent to participati forms. We removed the day reference to it, propor referencing it. Some sites have revi through the study shu study.	ng several randomis lating this to remove 70,000 patients is re- er" We have clarifie cond time to PQIP. A heir electronic healt on in PQIP, in additi 3 questionnaire in 2 sed updates to the o ewed their capacity	sed clinical trials by the end date, and beached or at the end d that patients presund we have addece to record system, the on to our standard 2021 and some of the consent form and p to continue with the	y acting as a data rephrase: "End da d of recruitment of senting for a secor t that if a hospital h iat this can be use: REC approved pa he study documen rotocol will remove e study and have of	collection platforr tte - either when linked clinical di procedure can has an electronic d to evidence tient consent ts still make e wording decided to go	
				Specific stu	dy	
Project type (select):				Research tis	sue bank	
				Research da	tabase	
Has the study been reviewed by a UKECA-recognised Rese Committee (REC) prior to this amendment?:	earch Ethics	Ye	es		No	
				NHS/HSC R	EC	
What type of UKECA-recognised Research Ethics Committee is applicable? (select):	ee (REC) leview			Ministry of D	efence (MoDREC	
Is all or part of this amendment being resubmitted to the Res Committee (REC) as a <b>modified amendment</b> (i.e. a substa previously given an unfavourable opinion)?		Ye	es	I	Νο	
Where is the NHS/HSC Research Ethics Committee (REC)	that reviewed the	England	Wales	Scotland	Northern Irelan	
study based?:		Yes	No	No	No	
Was the study a clinical trial of an investigational medicinal OR does the amendment make it one?:	product (CTIMP)	Ye	es		No	
Was the study a clinical investigation or other study of a me does the amendment make it one?:	dical device OR	Ye	es	1	No	
Did the study involve the administration of radioactive substa requiring ARSAC review, OR does the amendment introduce		Ye	es	I	No	
Did the study involve the use of research exposures to ionisi involving the administration of radioactive substances) OR d amendment introduce this?:		Ye	es	1	No	
Did the study involve adults lacking capacity OR does the an introduce this?:	mendment	Ye	es		No	
Did the study involve access to confidential patient informati direct care team without consent OR does the amendment in		Ye	es	I	No	
Did the study involve prisoners or young offenders who are i supervised by the probation service OR does the amendment		Ye	es	I	No	
Did the study involve children OR does the amendment intro	oduce this?:	Ye	es		No	
Did the study involve NHS/HSC organisations prior to this an	mendment?:	Ye	es		No	
Did the study involve non-NHS/HSC organisations OR does introduce them?:	the amendment	Ye	es	I	No	
		England	Wales	Scotland	Northern Irelar	
Lead nation for the study:		Yes	No	No	No	
	or to this					
Which nations had participating NHS/HSC organisations pri- amendment?		Yes	Yes	Yes	Yes	

Which nations had participating non-NHS/HSC organisations prior to this amendment?	Yes	No	No	No
Which nations will have participating non-NHS/HSC organisations after this amendment?	Yes	No	No	No

### Section 2: Summary of change(s)

Please note: Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

	Change 1				
Area of change (select)*:	Study Documents				
Specific change (select - only available when area of change is selected first)*:	Protocol - Substantial	changes (e.g. affe	cting safety or the s	scientific value of th	ne trial)
Further information (free text - note that this field will adapt to the amount of text entered):	Change to study end o	date.			
Applicability:		England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located this change?*:	that will be affected by	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by some? ( <b>please note</b> that this answer may affect the categor		A	AII	Sc	ome
Where are the participating non-NHS/HSC organisations loc affected by this change?*:	cated that will be	Yes	No	No	No
				Remove all c	hanges below

	Change 2				
Area of change (select)*:	Study Documents				
Specific change (select - only available when area of change is selected first)*:	Protocol - Non-substa	ntial changes (e.g.	not affecting safety	y or the scientific va	alue of the trial)
Further information (free text - note that this field will adapt to the amount of text entered):	Removal of wording re	eferring to the day a	3 questionnaire.		
Applicability:		England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located this change?*:	d that will be affected by	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by some? (please note that this answer may affect the categor	0, ,	A	JI	Sc	ome
Where are the participating non-NHS/HSC organisations loo affected by this change?*:	cated that will be	Yes	No	No	No
				Remove all c	hanges below

	Change 3				
Area of change (select)*:	Participating Organisa	itions			
Specific change (select - only available when area of change is selected first)*:	Early closure or withd	rawal of research s	sites		
Further information (free text - note that this field will adapt to the amount of text entered):	Closure of: - The Shrewsbury and - Hampshire Hospitals				
Applicability:		England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located this change?*:	I that will be affected by	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by some? ( <b>please note</b> that this answer may affect the categor		ŀ	AII	Sc	ome
Where are the participating non-NHS/HSC organisations loc affected by this change?*:	cated that will be	Yes	No	No	No
				Remove all c	hanges below

	Change 4				
Area of change (select)*:	Study Design				
Specific change (select - only available when area of change is selected first)*:	Other significant changed place at participating of				ng resource in
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	Allowing the recruitme second time to PQIP. Allowing hospitals to u Change to end of stud	ise electronic cons	·		
Applicability:		England	Wales	Scotland	Northern Irelan
Where are the participating NHS/HSC organisations located this change?*:	that will be affected by	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by some? ( <b>please note</b> that this answer may affect the categories of the source of t		A	ll	Sc	ome
Where are the participating non-NHS/HSC organisations loc affected by this change?*:	ated that will be	Yes	No	No	No
				Add anoth	ner change

# Section 3: Declaration(s) and lock for submission Declaration by the Sponsor or authorised delegate

## · I confirm that the Sponsor takes responsibility for the completed amendment tool

· I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Name [first name and surname]*:	Pushpsen Joshi
Email address*:	pushpsen.joshi1@nhs.net

#### Lock for submission

Please note: This button will only become available when all mandatory (\*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

Lock for submission

After locking the tool, proceed to submit the amendment online. The "Submission Guidance" tab provides further information about the next steps for the amendment.

#### Section 4: Review bodies for the amendment

Please note: This section is for information only. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

								F	Review	bodie	s								
			UK ۱	wide:			Eng	land a	nd Wa	ales:		Scot	land:		N	ortherr	n Irelar	nd:	
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	SddWH	HRA and HCRW Approval	REC (AWIA)	рврр	SPS (RAEC)	National coordinating function	HSC REC	HSC Data Guardians	Prisons	National coordinating function	Category:
Change 1:	Υ					Y				(Y)				(Y)				(Y)	А
Change 2:	Ν					(Y)				(Y)				(Y)				(Y)	А
Change 3:	Ν					(Y)				(Y)				(Y)				(Y)	А
Change 4:	Υ					Y				Υ				Y				Υ	С
Overall reviews for the amendmer	it:																		
Full review:	Υ					Υ				Υ				Υ				Υ	
Notification only:	Ν					Ν				Ν				Ν				Ν	

Overall amendment type:	Substantial
Overall Category:	A